Compared to C-GCA, patients with large vessel involvement (LV-GCA and LV-C-GCA) were younger and more frequently women, and the difference was further significant for patients with isolated LV-GCA. Patients with isolated LV-GCA had also the longer duration of symptoms at GCA diagnosis [LV-GCA 20(16-82) vs LV-C-GCA 12(4-16) vs C-GCA 4(3-12) weeks; $p<0.001$]. Systemic symptoms, as fever and fatigue, were associated with large vessel involvement, both in LV-GCA and LV-C-GCA groups. Polymyalgia rheumatica was equally reported in all three cohorts of patients and no significant differences were found in inflammatory markers levels according to vessel involvement.

In patients with large vessels involvement (LV-GCA and LV-C-GCA) thoracic aorta, subclavian arteries and abdominal aorta were the most frequently involved arteries.

Conclusion: GCA is not a single entity but includes several patterns of disease. Female gender, younger age and systemic symptoms are associated with large vessel involvement, regardless the presence or absence of cranial symptoms. The different clinical manifestations of large vessel GCA lead to a longer time to diagnosis if compared to C-GCA. For these reasons, in patients with the aforementioned characteristics, a large vessel involvement should be considered in order to reduce the time to diagnosis.

REFERENCES:

- [1] De Boysson H, et al. Clin Exp Rheumatol 2019.
- [2] Prieto-González S, et al. Ann Rheum Dis 2012.
- [3] Brack A, et al. Arthritis Rheum 1999.
- [4] Muratore F, et al. Rheumatol 2015.

	GCA (n: 100)	C-GCA (n: 61)	LV-C-GCA (n: 23)	LV-GCA (n: 16)	p
Age: median (IQR)	76 (67-79)	75 (71-80)	74 (69-77)	63 (59-72)	0.001
Female/ Male	68 (68%) / 32 (32%)	38 (62%) / 23 (38%)	17 (74%) / 6 (26%)	13 (81%) / 3 (19%)	0.276
Time between symptom onset and diagnosis (weeks)	8 (4-20)	4 (3-12)	12 (4-16)	20 (16-82)	<0.001
Cranial symptoms (overall)	84 (84%)	61 (100%)	23 (100%)	0 (0%)	<0.001
New temporal headache	77 (77%)	58 (95%)	19 (83%)	0 (0%)	<0.001
Visual symptoms	39 (39%)	34 (56%)	5 (22%)	0 (0%)	<0.001
Jaw or tongue claudication	35 (35%)	27 (44%)	8 (35%)	0 (0%)	0.004
Fever	48 (48%)	23 (38%)	14 (61%)	11 (69%)	0.032
Fatigue	75 (75%)	40 (66%)	21 (91%)	14 (88%)	0.023
Weight loss	52 (52%)	28 (46%)	13 (57%)	11 (69%)	0.235
Polymyalgia rheumatica	43 (43%)	27 (44%)	13 (57%)	3 (19%)	0.061
Arm or leg claudication	5 (5%)	0 (0%)	4 (17%)	1 (6%)	0.005
CRP (C-reactive protein)	83 (45-127)	77 (39-115)	89 (50-134)	95 (20-124)	0.461
ESR (erythrocyte sedimentation rate)	72 (47-96)	70 (46-88)	75 (28-105)	66 (44-91)	0.711
Cranial arteries	84 (84%)	61 (100%)	23 (100%)	0 (0%)	<0.001
Carotid arteries	19 (19%)	0 (0%)	12 (52%)	7 (44%)	<0.001
Subclavian and upper limb arteries	21 (21%)	0 (0%)	10 (43%)	11 (69%)	<0.001
Thoracic aorta	29 (29%)	0 (0%)	15 (65%)	14 (88%)	<0.001
Abdominal aorta	21 (21%)	0 (0%)	10 (43%)	11 (69%)	<0.001
Iliac and inferior limb arteries	10 (10%)	0 (0%)	6 (26%)	4 (25%)	<0.001

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.510

POS0798

GIANT CELL ARTERITIS TREATMENT PATTERNS AND RATES OF SERIOUS INFECTIONS

S. Tedeschi¹, Y. Jin², S. Vine², H. Lee², A. Pethoe-Schramm³, V. Yau⁴, S. Kim^{1,2}. ¹Brigham and Women's Hospital, Rheumatology, Inflammation and Immunity, Boston, United States of America; ²Brigham and Women's Hospital, Pharmacoeconomics and Pharmacoeconomics, Boston, United States of America; ³F. Hoffmann-La Roche Ltd., Global Medical Affairs - Immunology, Basel, Switzerland; ⁴Genentech, Personalized Healthcare Data Science, South San Francisco, United States of America

Background: Giant cell arteritis (GCA) afflicts older adults, who may have age- and comorbidity-related risks for infection, and is treated with glucocorticoids and other immunosuppressants that might increase the risk of serious infections.

Objectives: To examine GCA treatment patterns and rates of serious infections in two real-world cohorts in the U.S.

Methods: Using claims data from two U.S. health insurance databases, Medicare (public, 2007-2017) and MarketScan (commercial, 2015-2019), we selected a cohort of patients with GCA based on a validated claims-based algorithm requiring ≥ 2 diagnosis codes for GCA plus dispensing of high-dose oral glucocorticoid (PPV 84.8%) [1]. The Medicare cohort included Medicare enrollees aged ≥ 65 years with GCA who were treated at a large Massachusetts-based healthcare system; the MarketScan cohort included a nationwide sample of GCA patients aged ≥ 50 years. GCA index date was the date of 1st glucocorticoid prescription. We assessed baseline comorbidities in the year prior to index date. Immunosuppressants and prophylactic antibiotics dispensed within 30 days

of index date were recorded. Influenza vaccine administration in the year after index date was identified. We calculated the incidence rate of serious infections, defined as infections requiring hospitalization, after index date through end of cohort follow-up (12/31/17 in Medicare; 12/31/2019 in MarketScan), disenrollment, or death.

Results: The Medicare cohort included 734 patients, 28% male, mean age 77.1 (SD 7.4); the MarketScan cohort included 1022 patients, 30% male, mean age 68.4 (SD 10.9). The most common comorbidity was hypertension (80% Medicare; 72% MarketScan) followed by hyperlipidemia, cancer, coronary artery disease, and diabetes (Table 1). High-dose prednisone was the most common initial treatment; a small percentage received tocilizumab within 30 days of index date. Prophylaxis against pneumocystis pneumonia was similar in Medicare (13%) and MarketScan cohorts (10%). Influenza vaccination was more common in the Medicare (56%) than MarketScan (22%) cohort in the year after GCA index date. During the mean follow-up time of 2.6 (SD 2.5) years in Medicare and 1.5 (SD 0.9) years in MarketScan, 27.9% of the Medicare and 7.2% of MarketScan patients developed serious infections: incidence rate per 100 person-years = 10.7 (95% CI 9.3, 12.2) in Medicare and 6.3 (95% CI 5.0, 7.9) in MarketScan.

Conclusion: In these 2 real-world GCA cohorts in the US, over 25% of Medicare and 7% of MarketScan patients developed serious infection during follow-up. The incidence rate of serious infection was similar to ANCA-associated vasculitis [2]. Use of prophylactic antibiotics and influenza vaccination was suboptimal among GCA patients.

REFERENCES:

- [1] Lee H, et al. ACR Open Rheum 2020 (in press).
- [2] Rathmann J, et al. Rheumatology 2020; doi: 10.1093/rheumatology/keaa699.

Table 1. Comorbidities, medication use, and infection rates in GCA cohorts

	Medicare cohort (n=734)	MarketScan cohort (n=1022)
Baseline comorbidities		
Hypertension	80%	72%
Hyperlipidemia	71%	61%
Cancer	38%	24%
Coronary artery disease	34%	25%
Diabetes	34%	31%
No. rheumatology visits, mean (SD)	1.4 (2.2)	0.8 (1.7)
Medications within 30 days of index date		
Prednisone maximum dose ≥ 60 mg daily	87%	91%
Tocilizumab IV or SC	<2%	5%
Methotrexate	3%	4%
Bactrim, atovaquone, or dapsone	13%	10%
Vaccines in the year after index date		
Influenza vaccine	56%	22%
Serious infection incidence rate (95% CI) per 100 person-years	10.7 (9.3, 12.2)	6.3 (5.0, 7.9)

Disclosure of Interests: Sara Tedeschi: None declared, Yinzhu Jin: None declared, Seanna Vine: None declared, Hemin Lee: None declared, Attila Pethoe-Schramm Employee of: F. Hoffmann-La Roche, Vincent Yau Employee of: F. Hoffmann-La Roche/Genentech, Seoyoung Kim Grant/research support from: Roche, Pfizer, AbbVie and Bristol-Myers Squibb

DOI: 10.1136/annrheumdis-2021-eular.561

POS0799

THE EFFICACY AND SAFETY OF TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Koster¹, K. J. Warrington¹, J. Han², S. Mohan³. ¹Mayo Clinic, Division of Rheumatology, Rochester, United States of America; ²Genentech, Inc., Biometrics, South San Francisco, United States of America; ³Genentech, Inc., Immunology, South San Francisco, United States of America

Background: Tocilizumab (TCZ) has been proven to be safe and effective for the treatment of giant cell arteritis (GCA) in 2 randomized controlled trials; however, data from additional types of studies provide valuable information related to the treatment of GCA with TCZ.

Objectives: To review and analyze efficacy and safety data for TCZ in GCA based on peer-reviewed publications to date.

Methods: A systematic literature review was conducted according to the PRISMA guidelines. Publications were retrieved from the MEDLINE, Embase, Cochrane, Scopus and Web of Science databases. Publications of clinical trials and retrospective or prospective observational studies (April 11, 2005-October 8, 2019) including patients with GCA (classified based on ACR criteria and/or positive biopsy vs imaging) treated with TCZ and reporting a measure of efficacy were eligible for inclusion. Extracted data included year of publication, year(s) when the study was conducted, number of patients with GCA, method of GCA diagnosis, age and sex, TCZ treatment details (dose, route of administration, frequency, duration), clinical outcome (remission, relapse), serious adverse events